Index to Volume 3, 2005 (issue:page)

• Abilify, 2:2,4


• Adderall, 4:4-6


• ADHD, 4:1-8


• Agitation in dementia, 8:4-5


• Alcoholism, 9:4-6


• Alzheimer’s disease, 8:1


• Ambien, 9:2


• Antidepressant augmentation, 1:5


• Aricept, 8:2


• Atypical antipsychotics, 2:1-8,8:6


• Benzodiazepines, 9:1-8


• Body Mass Index, 5:4


• Bipolar depression, 6:1


• Cholinesterase inhibitors, 8:1


• Clozaril, 2:1


• CME Bias, 3:1


• Concerta, 4:2-3


• Conflict of Interest, 3:4-5


• Cymbalta, 1:1


• Depakote in women, 10:4-5


• Dexatrim, 5:6


• Dexedrine, 4:2-3


• Diabetes and atypicals, 2:1


• Drug Industry Influence, 3:1-8


• ECT, 1:1


• Effexor, 1:1


• Equetro, 6:1


• Focalin, 4:2-3


• Genetics and psychiatry, 11:1-8


• Genetic counseling, 11:1


• Generic antidepressants, 1:6


• Geodon, 2:1,4


• HIPAA, 7:4-6


• Hypnotics, 9:1


• Indiplon, 9:2


• Insomnia, 9:1


• Lab monitoring, 6:6


• Lamictal, 6:4-5,10:4


• Lexapro, 1:5


• Lunesta, 9:1


• “Mars and Venus”: 12:4-5


• Meridia, 5:6


• Metabolic Side Effects, 2:1,5:4-5


• Namenda, 8:1


• Nicotine Replacement, 5:3


• Nortriptyline, 5:3


• P450 genotyping, 11:1


• Paxil, 10:3


• Postpartum depression, 10:1


• Pregnancy, 10:1-8


• Progress note, 7:1


• Psychostimulants, 4:1-3


• Psychotherapy for ADHD, 4:1


• QT prolongation, 2:4


• Rating scales, 7:1


• Risperdal, 2:1


• Ritalin, 4:2


• Rozerem, 9:1


• Schizophrenia, 5:4-5


• Seroquel, 2:1


• Self-Help books, 12:1-8


• Serzone, 1:6


• Smoking Cessation, 5:1


• SOAP note, 7:2


• Sonata, 9:2


• SSRIs in pregnancy, 10:1


• Strattera, 4:3


• Tegretol, 6:2


• Thyroid augmentation, 1:5


• Topamax, 10:5


• Transcranial Magnetic Simulation, 1:1


• Vagus nerve stimulation, 1:6


• Weight loss, 5:1


• Xenical, 5:6


• Zyban, 5:3


• Zyprexa, 2:1

Articles in Volume 3, 2005

• The Dual Reuptake Wars


• rTMS: Will It Replace ECT?


• Antidepressant Updates: Generics, VNS, & Serzone


• Michael J. Gitlin on Using the Newer Antidepressants

• Metabolic Side Effects: Here We Go Again!


• Clozapine: Is it Truly Better Than the Rest?


• Atypicals for Bipolar: And Then There Were Five


• Philip G. Janicak, on Using Atypical Antipsychotics

• How to Sniff Out Bias in CME Programs


• Journal Articles as Marketing: Tricks of the Trade


• CME Bias: ACCME to the Rescue!


• Jerome P. Kassirer, on Conflict of Interest in Medicine

• Psychostimulants and Strattera Explained


• Therapy vs. Meds for ADHD: Lessons from the MTA Study


• Adderall and Death: It’s Team FDA vs. Team Canada!


• Lawrence H. Diller, on The Use of Stimulants in ADHD

• How to Help Your Patients Lose Weight


• Smoking Cessation: An Update


• Laurence Guttmacher on Medical Screening in Schizophrenia

• Equetro: New Name, Old Drug


• Antidepressants in Bipolar Disorder: The Controversy Continues


• Lab Monitoring with Mood Stabilizers: Let’s Get Real


• Ivan Goldberg on Treating Bipolar Depression

• The Humble Progress Note


• Using Psychiatric Rating Scales in Clinical Practice


• HIPAA Compliance for Psychiatrists: A One-Stop Shop


• Rebecca Brendel on HIPAA and Psychiatric Practice

• Cholinesterase Inhibitors: Under Siege


• Namenda: Pining for Another Indication


• Rosack’s FDA Watch: Atypical Antipsychotics and the Elderly


• Marc Agronin on Treating Agitation in Dementia

• Lunesta, Rozerem, and More: It’s Showtime for the New Hypnotics


• Getting Patients off Benzos: Tips from Old Masters


• Should We Prescribe Benzos to Alcohol Abusers?


• John Talmadge on Using Benzodiazepines

• Antidepressants and Pregnancy: Now What Should We Tell Our Patients?


• Treating Postpartum Depression: A Look at the Evidence


• Victoria Hendrick on Drug Interactions and Side Effects Specific to Women

• P450 Genotyping: Ready for Prime Time?


• Genetic Counseling: A Primer for Psychiatrists


• Samuel H. Barondes on Genetic Research in Psychiatry

• TCR’s Top Self-Help Books in Psychiatry


• 2005 Index


• John Gray on The Essence of Mars and Venus